Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies

1 Jul 2021

Abstract excerpt

BACKGROUND: Latent membrane protein-2A (LMP2A)-specific TCR-engineered T cells could be a promising treatment approach to Epstein-Barr virus-associated malignancies. However, previous studies mainly reported LMP2A-reactive TCRs only focusing on specific HLA subtypes and corresponding epitopes, and thus, they were only suitable for patients with specific HLA. METHODS: Due to hugely varied HLA subtypes and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34210819
DOI: 10.1136/jitc-2021-002516

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignanciesPMID 34210819Read ↗

TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignanciesSemantic proximity Read ↗

Identification of a TAP-Independent, Immunoproteasome-Dependent CD8<sup>+</sup>T-Cell Epitope in Epstein-Barr Virus Latent Membrane Protein 2Semantic proximity Read ↗

Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402–restricted Epstein-Barr virus–specific CD8+ T cellsSemantic proximity Read ↗

Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications.Semantic proximity Read ↗

Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell ModelSemantic proximity Read ↗

Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein–Barr virus as a potential vaccine and diagnostic agentSemantic proximity Read ↗

Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target AntigensSemantic proximity Read ↗

HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2Semantic proximity Read ↗

A Multidimensional Workflow Profiling of Allogeneic EBV-Specific T-cell Therapies Reveals Potency-Linked SignaturesSemantic proximity Read ↗

Dual non-contiguous peptide occupancy of HLA class I evoke antiviral human CD8 T cell response and form neo-epitopes with self-antigens.Semantic proximity Read ↗

Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapySemantic proximity Read ↗

Immortalization and functional screening of natively paired human T cell receptor repertoiresSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.